Vorasidenib (Synonyms: AG-881) |
Katalog-Nr.GC19380 |
Vorasidenib (AG-881) ist ein oral verfÜgbarer, hirngÄngiger Inhibitor der zweiten Generation der dual mutanten Isocitrat-Dehydrogenasen 1 und 2 (mIDH1/2). Vorasidenib (AG-881) zeigt eine nanomolare Hemmung von (D)-2-Hydroxyglutarat (D-2-HG) und die IC50-Bereiche von 0,04 bis 22 nM gegen IDH1 R132C, IDH1 R132G, IDH1 R132H und IDH1 R132S und 7 bis 14 nM gegen IDH2 R140Q und 130 nM gegen IDH2 R172K.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1644545-52-7
Sample solution is provided at 25 µL, 10mM.
Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K[1][2].
Vorasidenib has strong antiproliferative activity against human glioblastoma U-87 MG pLVX-IDH2 R140Q-neo, fibrosarcoma HT-1080 and neurosphere TS603 cells, all with IC50s of less than 50 nM[2].
References:
[1]. Fujii T, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016 May;21(117):373-80.
[2]. Ma T, et al. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. J Med Chem. 2018 Oct 25;61(20):8981-9003.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *